Altered microbiota and inflammation associated with irritable bowel disease (IBD) appear to make it more difficult for patients to fight off Clostridioides difficile infection, according to a recent ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides ...

Risk for Clostridioides difficile (C. diff) infection wasn't any greater with vedolizumab (Entyvio) versus anti-tumor necrosis factor (TNF) agents for ulcerative colitis, a researcher reported. In a ...

VE202 was well tolerated, with no reports of treatment-related serious adverse events Additional analyses from COLLECTiVE202 to be shared in upcoming scientific forums Vedanta to focus resources on ...

Research at North Carolina State University shows that the CRISPR-Cas system can be used to effectively target and eliminate specific gut bacteria, in this case Clostridioides difficile, the pathogen ...

Since its introduction in 2011, adoption of diverting loop ileostomy for fulminant Clostridioides difficile colitis has more than doubled, and the procedure appeared to be a viable alternative to ...

Vedolizumab (Entyvio) treatment was linked with a lower risk of some infections compared with tumor necrosis factor (TNF) antagonists in patients with ulcerative colitis (UC), researchers reported. An ...

Research at North Carolina State University shows that the CRISPR-Cas system can be used to effectively target and eliminate specific gut bacteria, in this case Clostridioides difficile, the pathogen ...

A new study from the University of Birmingham has shown that fecal microbiota transplants (FMT) are highly successful in treating patients with Clostridioides difficile (C. diff) infection. A new ...

Gastrointestinal tumors remain a global health challenge, with high incidence and mortality. Among them, colorectal cancer (CRC) carries the heaviest burden and serves as a key model for how the gut ...